News
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
— Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA®
ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, today announced the expansion of its ongoing Phase I clinical trial of IOS-1002 in combination with MSD (Merck & Co., Inc., Rahway, NJ, USA)’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced solid tumors.
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
— Favorable safety profile of resorbable breast scaffolds in one-year follow-up
— No major scaffold-related complications or scaffold removals
— BellaSeno will initiate multicenter pivotal clinical trial with more than 100 patients
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that 10 breast scaffold patients and 5 pectus patients have successfully passed one-year follow-up in BellaSeno´s Australian clinical trials.
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
– Experienced biopharma professional focused on drug product development
Thermosome, a drug development company focused on targeted tumor therapies, today announced the appointment of Dr. Sabine Hauck as Chief Technology Officer (CTO).
Dr. Sabine Hauck is a highly experienced biopharmaceutical professional. She has been working in the field of drug product development in biopharma and specialty pharma for more than 20 years. Notably, she brings more than a decade of experience with liposomal products. Her expertise covers process development, chemistry, manufacturing and controls as well as bioanalytics, quality management and regulatory affairs. Read more…
BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
— Funding to support establishment of the world´s first fully automated production facility for resorbable medical scaffolds based in Australia
— AI-driven, no-touch manufacturing to ensure highest quality, safety and sterility levels
— Designed to manufacture up to 100,000 scaffolds per annum at full capacity
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that its Australian subsidiary has received financial assistance through the Queensland Government’s Industry Partnership Program.